Overview
Compare with MIMEDX GROUP, INC., CryoLife or TACTILE SYSTEMS TECHNOLOGY INC, or pick any stock.
- TickerARAY on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersMadison, Wisconsin1
- Incorporated inDE3
- Business address1240 Deming Way, Madison, Wi 537173
- Filer categoryAccelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports treatment delivery, planning, imaging and data management solutions designed to help clinical teams deliver precise radiation treatments across a broad range of clinical cases. Our portfolio includes the CyberKnife robotic platform and a differentiated helical portfolio that includes the Accuray Stellar, Radixact, Accuray Helix and Tomo C Systems, where available. We believe these solutions provide clinicians with advanced capabilities to support accuracy, flexibility, motion management, image guidance, adaptive workflows and personalized treatment delivery.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
27.7%Gross margin2
-6.6%Operating margin2
-12.2%Net margin2
-12.3%Revenue growth, 20262
-118.0%Return on equity2
3.51×Debt to equity2
-$12.8MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Service brought in 57% of the revenue ACCURAY INC broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2024 | 2025 | 2026 |
|---|---|---|---|
| Service | $212.4M | $220.9M | $229.2M |
| Product | $234.2M | $237.6M | $172.7M |
Regions
Eimea brought in 38% of the revenue ACCURAY INC broke down this way in fiscal 2026.
Regions by year
| Regions | 2024 | 2025 | 2026 |
|---|---|---|---|
| Eimea | $168.6M | $144.3M | $150.9M |
| Americas | $90.2M | $88.8M | $90.0M |
| China | $103.4M | $124.5M | $68.1M |
| Asia Pacific | $28.7M | $47.4M | $48.7M |
| Japan | $55.7M | $53.6M | $44.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue72¢$290.5M
- Research and development9¢$37.8M
- Other costs18¢$71.8M
- Income tax0¢$1.9M
Out of $401.9M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Gross profit | $111.5M | $147.0M |
| Research and development | $37.8M | $47.9M |
| Selling and marketing | $38.6M | $43.3M |
| General and administrative | $45.4M | $47.9M |
| Restructuring | $16.2M | $0 |
| Total operating expenses | $137.9M | $139.1M |
| Income (loss) from operations | -$26.4M | $7.8M |
| Income from equity method investment | $1.1M | $4.7M |
| Interest expense | -$32.9M | -$13.0M |
| Gain on extinguishment of debt | $0 | $1.5M |
| IEEPA refund financing costs | -$2.4M | $0 |
| Gain (loss) from change in fair value of warrant liability | $8.4M | -$499.0K |
| Other income, net | $5.0M | $559.0K |
| Income (loss) before provision for income taxes | -$47.2M | $1.1M |
| Provision for income taxes | $1.9M | $2.7M |
| Net loss | -$49.2M | -$1.6M |
| Net loss per share - basic and diluted (in dollars per share) | -$0.40 | -$0.02 |
| Basic and diluted (in shares) | 122.6M shares | 102.8M shares |
| Unrealized gain from cash flow hedges, net of reclassifications | $1.6M | $0 |
| Foreign currency translation adjustment | -$3.2M | $1.6M |
| Change in defined benefit pension obligation | -$42.0K | $828.0K |
| Comprehensive income (loss) | -$50.9M | $794.0K |
| Revenue from Contract with Customer | $401.9M | $458.5M |
| Cost of Revenue | $290.5M | $311.5M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $40.6M | $57.4M | ||
| Restricted cash | $611.0K | $574.0K | ||
| Accounts Receivable, Allowance for Credit Loss, Current, Net | $67.4M | $83.2M | ||
| Inventories | $147.1M | $141.0M | ||
| Prepaid expenses and other current assets | $31.8M | $33.5M | ||
| Deferred cost of revenue | $276.0K | $1.8M | ||
| Total current assets | $287.8M | $317.5M | ||
| Property and equipment, net | $27.3M | $28.7M | ||
| Carrying value of investment in joint venture | $5.0M | $4.6M | ||
| Operating lease right-of-use assets, net | $27.5M | $33.1M | $33.8M | |
| Goodwill | $57.9M | $57.8M | $57.7M | |
| Restricted cash | $7.5M | $4.1M | ||
| Other assets | $30.6M | $24.4M | ||
| Total assets | $443.7M | $470.2M | ||
| Accounts payable | $40.6M | $34.0M | ||
| Accrued compensation | $15.7M | $14.6M | ||
| Operating lease liabilities | $8.2M | $7.4M | ||
| Other accrued liabilities | $32.2M | $29.4M | ||
| Customer advances | $10.4M | $12.2M | ||
| Deferred revenue, current | $82.8M | $82.8M | $82.3M | |
| Short-term debt, net | $1.5M | $12.7M | ||
| Total current liabilities | $191.4M | $192.6M | ||
| Noncurrent portion of operating lease obligations | $27.8M | $32.5M | ||
| Long-term other liabilities | $5.5M | $5.2M | ||
| Warrant liability | $2.4M | $8.5M | ||
| Deferred revenue, non-current | $28.5M | $28.5M | $26.6M | |
| Long-term debt, net | $146.4M | $123.8M | ||
| Total liabilities | $402.0M | $389.1M | ||
| Common stock, $0.001 par value; authorized: 200,000,000 shares as of June 30, 2026, and June 30, 2025, respectively; 122,541,809 shares issued and 119,433,440 shares outstanding as of June 30, 2026, and 115,752,221 shares issued and 112,643,852 shares outstanding as of June 30, 2025. | $119.0K | $113.0K | ||
| Additional paid-in-capital | $613.6M | $602.2M | ||
| Accumulated other comprehensive loss | -$3.5M | -$1.8M | ||
| Accumulated deficit | -$568.5M | -$519.3M | ||
| Total stockholders equity | $41.7M | $81.2M | $45.1M | |
| Total liabilities and stockholders equity | $443.7M | $470.2M | ||
| Accounts Receivable, Allowance for Credit Loss, Current | $884.0K | $369.0K | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued (in shares) | 122.5M shares | 115.8M shares | ||
| Common stock, shares outstanding (in shares) | 119.4M shares | 112.6M shares |
| Period ending | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $40.6M | $57.4M | ||
| Restricted cash | $611.0K | $574.0K | ||
| Accounts Receivable, Allowance for Credit Loss, Current, Net | $67.4M | $83.2M | ||
| Inventories | $147.1M | $141.0M | ||
| Prepaid expenses and other current assets | $31.8M | $33.5M | ||
| Deferred cost of revenue | $276.0K | $1.8M | ||
| Total current assets | $287.8M | $317.5M | ||
| Property and equipment, net | $27.3M | $28.7M | ||
| Carrying value of investment in joint venture | $5.0M | $4.6M | ||
| Operating lease right-of-use assets, net | $27.5M | $33.1M | $33.8M | |
| Goodwill | $57.9M | $57.8M | $57.7M | |
| Restricted cash | $7.5M | $4.1M | ||
| Other assets | $30.6M | $24.4M | ||
| Total assets | $443.7M | $470.2M | ||
| Accounts payable | $40.6M | $34.0M | ||
| Accrued compensation | $15.7M | $14.6M | ||
| Operating lease liabilities | $8.2M | $7.4M | ||
| Other accrued liabilities | $32.2M | $29.4M | ||
| Customer advances | $10.4M | $12.2M | ||
| Deferred revenue, current | $82.8M | $82.8M | $82.3M | |
| Short-term debt, net | $1.5M | $12.7M | ||
| Total current liabilities | $191.4M | $192.6M | ||
| Noncurrent portion of operating lease obligations | $27.8M | $32.5M | ||
| Long-term other liabilities | $5.5M | $5.2M | ||
| Warrant liability | $2.4M | $8.5M | ||
| Deferred revenue, non-current | $28.5M | $28.5M | $26.6M | |
| Long-term debt, net | $146.4M | $123.8M | ||
| Total liabilities | $402.0M | $389.1M | ||
| Common stock, $0.001 par value; authorized: 200,000,000 shares as of June 30, 2026, and June 30, 2025, respectively; 122,541,809 shares issued and 119,433,440 shares outstanding as of June 30, 2026, and 115,752,221 shares issued and 112,643,852 shares outstanding as of June 30, 2025. | $119.0K | $113.0K | ||
| Additional paid-in-capital | $613.6M | $602.2M | ||
| Accumulated other comprehensive loss | -$3.5M | -$1.8M | ||
| Accumulated deficit | -$568.5M | -$519.3M | ||
| Total stockholders equity | $41.7M | $81.2M | $45.1M | |
| Total liabilities and stockholders equity | $443.7M | $470.2M | ||
| Accounts Receivable, Allowance for Credit Loss, Current | $884.0K | $369.0K | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued (in shares) | 122.5M shares | 115.8M shares | ||
| Common stock, shares outstanding (in shares) | 119.4M shares | 112.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$49.2M | -$1.6M |
| Depreciation and amortization | $7.9M | $6.2M |
| Share-based compensation | $6.5M | $10.2M |
| Amortization of debt financing costs and discount for warrants issued to lenders | $8.1M | $1.4M |
| Gain on extinguishment of debt | $0 | -$1.5M |
| Non-cash interest paid-in-kind | $9.7M | $616.0K |
| Gain (loss) from change in fair value of warrant liability | -$8.4M | $499.0K |
| Provision for (recovery of) credit losses | $573.0K | -$101.0K |
| Provision for write-down of inventories | $3.6M | $2.2M |
| Asset Impairments | $2.4M | $0 |
| Loss on disposal of property and equipment | $538.0K | $0 |
| Income from equity method investment | -$1.1M | -$4.7M |
| Net deferred gross profit (loss) on sales to the JV | -$36.0K | $7.7M |
| Provision for deferred income taxes | $624.0K | $156.0K |
| Accounts receivable | $11.5M | $13.4M |
| Inventories | -$12.5M | -$9.1M |
| Prepaid expenses and other assets | -$8.0M | -$2.5M |
| Deferred cost of revenue | $1.5M | -$912.0K |
| Accounts payable | $5.2M | -$18.7M |
| Operating lease liabilities, net of operating lease right-of-use assets | $963.0K | $620.0K |
| Accrued compensation and accrued liabilities | $7.7M | -$5.9M |
| Customer advances | -$1.4M | -$2.4M |
| Deferred revenues | $7.0M | $7.4M |
| Net cash (used in) provided by operating activities | -$7.0M | $2.9M |
| Purchases of property and equipment, net | -$5.9M | -$4.3M |
| Capitalized costs for software to be sold | -$6.4M | -$4.3M |
| Net cash used in investing activities | -$12.3M | -$8.5M |
| Proceeds from the issuance of common stock to employees | $665.0K | $1.6M |
| Taxes paid related to net share settlement of equity awards | -$51.0K | -$90.0K |
| Debt financing costs | -$1.1M | -$13.3M |
| Paydown of 2026 Convertible Notes | -$18.0M | -$68.5M |
| Borrowings under Revolving Credit Facility | $19.0M | $27.0M |
| Repayments under Revolving Credit Facility | -$14.0M | -$37.0M |
| Proceeds from the IEEPA Financing Agreement | $6.6M | $0 |
| Payments of IEEPA refunds to third-party purchaser | -$2.8M | $0 |
| Net cash provided by (used in) financing activities | $7.0M | -$4.3M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -$1.1M | $1.7M |
| Net decrease in cash, cash equivalents and restricted cash | -$13.4M | -$8.3M |
| Cash paid for income taxes | $2.3M | $3.9M |
| Cash paid for interest | $13.9M | $9.7M |
| Fair value of stock issued to settle Convertible Notes | $0 | $11.1M |
| Fair value of warrants issued with debt | $6.6M | $21.1M |
| Unpaid purchase of property and equipment at end of year | $9.0K | $888.0K |
| Unpaid capitalized software costs at end of year | $0 | $258.0K |
| Transfers from inventory to property and equipment | $1.6M | $3.7M |
| Transfer of inventory to other assets | -$1.2M | $1.2M |
| Transfer of lease liabilities to leasehold improvements | $0 | $1.3M |
| Transfer of other assets to property and equipment | $0 | $242.0K |
| Financing obligation from uncollected IEEPA refunds | $2.8M | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
ACCURAY INC sits at the top of its group. 17 entities, 16 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of ACCURAY INC
- TCW GROUP INC Filed SCHEDULE 13D/A on ACCURAY INC, latest Sep 2, 2026 (4 filings since Jun 17, 2025)
- Neuberger Berman Filed SCHEDULE 13G/A on ACCURAY INC, latest Aug 5, 2026 (6 filings since Feb 11, 2022)
- BlackRock Filed SCHEDULE 13G/A on ACCURAY INC, latest Jul 27, 2026 (5 filings since Feb 7, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on ACCURAY INC, latest Mar 26, 2026 (4 filings since Feb 13, 2024)
- Aevum Pension Fund Filed SCHEDULE 13G/A on ACCURAY INC, latest Oct 2, 2025 (3 filings since Oct 2, 2024)
- Archon Capital Management LLC Filed SC 13G/A on ACCURAY INC, latest Sep 6, 2024 (3 filings since Feb 13, 2023)
- ACCURAY INC Madison, Wisconsin
- Accuray Accelerator Technology (Chengdu) Company Limited Subsidiary · China
- Accuray Asia Ltd. Subsidiary · Hong Kong
- Accuray Belgium BV Subsidiary · Belgium
- Accuray Brasil Comércio, Importação e Exportação de Equipamentos Médicos Ltda Subsidiary · Brazil
- Accuray Europe SAS Subsidiary · France
- Accuray International SARL Subsidiary · Switzerland
- Accuray Italy S.R.L Subsidiary · Italy
- Accuray Japan K.K. Subsidiary · Japan
- Accuray Medical Equipment (Canada) Ltd. Subsidiary · Canada
- Accuray Medical Equipment (India) Private Limited Subsidiary · India
- Accuray Medical Equipment (Rus) LLC. Subsidiary · Russia
- Accuray Medical Equipment (Shanghai) Co., Ltd. Subsidiary · China
- Accuray Medical Equipment GmbH Subsidiary · Germany
- Accuray Mexico, S.A. de C.V. Subsidiary · Mexico
- Accuray Spain, S.L.U. Subsidiary · Spain
- Accuray UK, Ltd. Subsidiary · United Kingdom
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What ACCURAY INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $107.9M2 Jun 30, 2026 | $106.6M2 Jun 30, 2025 | +1.3% |
| Accumulated depreciation | $80.6M2 Jun 30, 2026 | $77.9M2 Jun 30, 2025 | +3.5% |
| Property and equipment, net | $27.3M2 Jun 30, 2026 | $28.7M2 Jun 30, 2025 | −4.7% |
| Operating-lease assets (leased space) | $27.5M2 Jun 30, 2026 | $33.1M2 Jun 30, 2025 | −16.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $40.6M2 Jun 30, 2026 | $57.4M2 Jun 30, 2025 | −29.2% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $57.9M2 Jun 30, 2026 | $57.8M2 Jun 30, 2025 | +0.2% |
| Intangible assets, net (excluding goodwill) | $02 Jun 30, 2026 | $15.0K2 Jun 30, 2025 | −100.0% |
| Finite-lived intangibles, net | $15.0K14 Jun 30, 2025 | $59.0K14 Jun 30, 2024 | −74.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $147.1M2 Jun 30, 2026 | $141.0M2 Jun 30, 2025 | +4.3% |
| Raw materials | $50.4M2 Jun 30, 2026 | $49.0M2 Jun 30, 2025 | +2.8% |
| Work in process | $14.8M2 Jun 30, 2026 | $14.8M2 Jun 30, 2025 | −0.6% |
| Finished goods | $81.9M2 Jun 30, 2026 | $77.2M2 Jun 30, 2025 | +6.2% |
Properties, in its own words
Facilities
Our corporate headquarters are in Madison, Wisconsin. We lease approximately 405,000 square feet world-wide. We lease approximately 247,000 square feet in Madison, Wisconsin for product development, manufacturing, administrative, training and warehouse space. We lease approximately 59,000 square feet in Sunnyvale and Santa Clara, California for product research and development and administrative functions. As of July 1, 2026, we subleased 9,000 square feet of our Santa Clara office space to a third party. We lease approximately 20,000 square feet in Morges, Switzerland, for administrative functions, and lease approximately 5,400 square feet in Genolier, Switzerland for training. We lease approximately 42,000 square feet of space in a manufacturing facility in Chengdu, China. We also lease international offices in China; Hong Kong; Japan; Korea; India; and Spain.
The rest of Item 2
We believe our current facilities are adequate to meet our current needs, but additional space, including additional radiation shielded areas in which systems can be assembled and tested, may be required in the future to accommodate anticipated increases in manufacturing needs.
Item 2 of the 10-K filed Aug 27, 2026.5
Leadership
Who has led ACCURAY INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerNeve Stephen R. La Nov 4, 2025 to now15
- Chief executive officerSuzanne C. Winter Dec 3, 2024 to Nov 4, 202516
- Chief executive officerJoshua Levine Oct 19, 2012 to Nov 2, 202117
- Chief executive officerEuan Thomson Feb 7, 2007 to Oct 12, 201218
- PresidentSuzanne C. Winter Oct 4, 2021 to now19
- PresidentJoshua Levine Oct 19, 2012 to Aug 17, 202117
- PresidentEuan Thomson Feb 7, 2007 to Oct 12, 201218
- Chief financial officerAli Pervaiz May 17, 2022 to now20
- Chief financial officerBrandon W. Green Sep 9, 2021 to Sep 2, 202221
- Chief financial officerShigeyuki Hamamatsu Oct 3, 2018 to Dec 2, 202022
- Chief financial officerKevin Waters Sep 23, 2015 to Jul 6, 201823
- Chief financial officerGregory Lichtwardt Sep 9, 2013 to Nov 1, 201324
- Chief financial officerDerek A. Bertocci Jan 5, 2009 to Jun 3, 201325
- Chief operating officerAndrew J. Kirkpatrick Oct 3, 2019 to Dec 5, 201926
- Chief operating officerKelly Londy Nov 3, 2015 to Oct 6, 201727
- Chief operating officerChris Raanes Feb 7, 2007 to Nov 2, 201228
Board members and other officers (52)
- SVP, Chief Commercial OfficerPaul Michael Miele Apr 10, 2026 to now29
- SVP, Chief Operations OfficerLeonel Peralta Feb 13, 2025 to now30
- VP, Corporate ControllerGina Corradetti Jan 11, 2023 to Jan 5, 202431
- SVP, Chief Commercial OfficerSandeep Chalke May 16, 2022 to now32
- VP, Chief Accounting OfficerFranco N. Palomba Jun 15, 2022 to Aug 1, 202233
- SVP & Chief Commercial OfficerSuzanne C. Winter Oct 31, 2019 to Dec 2, 202034
- VP, Finance and CAOShigeyuki Hamamatsu Jan 30, 2018 to Aug 31, 201835
- SVP, Chief Admin OfficerPatrick Spine Oct 26, 2018 to Dec 4, 202336
- SVP, Global OperationsAndrew J. Kirkpatrick May 25, 2017 to Jul 5, 201937
- SVP, Chief Commercial OfficerLionel Hadjadjeba May 25, 2017 to Jun 4, 201938
- SVP & Interim GCAlaleh Nouri Feb 12, 2014 to Feb 12, 201439
- EVP, OperationsGregory Lichtwardt Nov 4, 2014 to Jul 10, 201540
- SVP Global OperationsRobert P. Ragusa Jan 10, 2013 to Nov 1, 201341
- SVP Chief Marketing OfficerEric Pauwels Jan 27, 2011 to Mar 1, 201142
- SVP, Chief Commercial OfficerKelly Londy Nov 8, 2011 to Jul 10, 201543
- Senior Vice President & ChiefDerek A. Bertocci Mar 6, 2009 to Mar 6, 200944
- SVP, Gen Counsel & Corp Sec.Darren J. Milliken May 22, 2009 to Sep 2, 200945
- SVP Gen CounselChristopher D. Mitchell Mar 3, 2008 to Sep 3, 200846
- SVP FinanceHolly Grey Sep 15, 2008 to Sep 15, 200947
- Sr. VP, CMOEric Lindquist Feb 7, 2007 to Sep 2, 201048
- Sr. VP, Worldwide SalesWade Hampton Feb 7, 2007 to Feb 7, 200749
- Sr VP Human ResourcesTheresa L. Dadone Jul 23, 2007 to Jul 23, 200750
- Board MemberJohn Adler Nov 14, 2007 to Nov 14, 200751
- Board memberSteven F. Mayer Jun 16, 2025 to now52
- Board memberNeve Stephen R. La Nov 4, 2025 to now15
- Board memberChan Galbato Nov 17, 2025 to now53
- Board memberRobert Kill Feb 7, 2023 to now54
- Board memberByron C. Scott Feb 17, 2021 to now55
- Board memberMika Nishimura Aug 25, 2021 to now56
- Board memberGrand Anne Bryce Le Jul 23, 2020 to now57
- Board memberJoshua Levine Oct 6, 2020 to Nov 2, 202158
- Board memberJames M. Hindman Sep 16, 2019 to now59
- Board memberBeverly A. Huss Jan 16, 2018 to now60
- Board memberJoseph E. Whitters Jul 24, 2018 to now61
- Board memberEmad T. Rizk Mar 22, 2013 to Dec 2, 201562
- Board memberRichard Pettingill May 17, 2012 to Nov 23, 202263
- Board memberJack Goldstein May 27, 2010 to Nov 24, 202064
- Board memberPeter Fine Jul 9, 2010 to Dec 2, 201165
- Board memberDennis L. Winger Sep 14, 2009 to Dec 4, 201766
- Board memberLouis J. Lavigne Jr. Sep 14, 2009 to Dec 2, 202067
- Board memberElizabeth H. Davila Feb 8, 2008 to May 3, 202368
- Board memberJohn P. Wareham Feb 8, 2008 to Feb 26, 201069
- Board memberEuan Thomson Feb 7, 2007 to Apr 26, 201018
- Board memberJohn Adler Feb 7, 2007 to Jan 7, 200970
- Board memberLi Yu Feb 7, 2007 to Apr 30, 201071
- Board memberRobert S. Weiss Feb 7, 2007 to Nov 20, 201972
- Board memberTed T.c. Tu Feb 7, 2007 to Feb 14, 200773
- Board memberWayne Wu Feb 7, 2007 to Dec 2, 201174
- General counselJesse Chew Oct 26, 2018 to Dec 3, 202475
- General counselAlaleh Nouri Apr 1, 2014 to Jul 6, 201876
- General counselDarren J. Milliken Nov 4, 2009 to Nov 1, 201377
- General counselChristopher D. Mitchell May 15, 2007 to May 25, 200778
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Accuray Accelerator Technology (Chengdu) Company Limited China4
- Accuray Asia Ltd. Hong Kong4
- Accuray Belgium BV Belgium4
- Accuray Brasil Comércio, Importação e Exportação de Equipamentos Médicos Ltda Brazil4
- Accuray Europe SAS France4
- Accuray International SARL Switzerland4
- Accuray Italy S.R.L Italy4
- Accuray Japan K.K. Japan4
- Accuray LLC Delaware4
- Accuray Medical Equipment (Canada) Ltd. Canada4
- Accuray Medical Equipment (India) Private Limited India4
- Accuray Medical Equipment (Rus) LLC. Russia4
- Accuray Medical Equipment (Shanghai) Co., Ltd. China4
- Accuray Medical Equipment GmbH Germany4
- Accuray Mexico, S.A. de C.V. Mexico4
- Accuray Spain, S.L.U. Spain4
- Accuray UK, Ltd. United Kingdom4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Oct 13, 20268-K Executive or director change79
- Oct 6, 20268-K Executive or director change; Shareholder vote; Other events80
- Aug 19, 20268-K Results of operations; Regulation FD disclosure81
- Aug 6, 20268-K Listing notice or transfer82
- Jul 29, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change83
- Jun 4, 20268-K Ended a material agreement; Regulation FD disclosure84
- May 6, 20268-K Results of operations; Regulation FD disclosure85
- Apr 28, 20268-K Executive or director change86
- Apr 7, 20268-K Entered a material agreement87
- Apr 6, 20268-K Regulation FD disclosure88
- Mar 19, 20268-K Executive or director change89
- Feb 17, 20268-K Regulation FD disclosure90
- Nov 4, 2025New chief executive Neve Stephen R. La becomes CEO15
- Dec 3, 2024New chief executive Suzanne C. Winter becomes CEO16
- Oct 19, 2012New chief executive Joshua Levine becomes CEO17
- Feb 7, 2007New chief executive Euan Thomson becomes CEO18
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/202691
When it reported results
- Aug 19, 2026Reported quarterly or annual results81
- May 6, 2026Reported quarterly or annual results85
- Feb 4, 2026Reported quarterly or annual results92
- Nov 5, 2025Reported quarterly or annual results93
- Oct 20, 2025Reported quarterly or annual results94
- Aug 13, 2025Reported quarterly or annual results95
- Apr 30, 2025Reported quarterly or annual results96
- Feb 5, 2025Reported quarterly or annual results97
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
348 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 68 major events, 180 insider forms, 25 large holders, 53 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 7, 20264 PRIMARY DOCUMENT EDGAR
- Oct 7, 20263 PRIMARY DOCUMENT EDGAR
- Oct 6, 20268-K EDGAR
- Oct 1, 20264 PRIMARY DOCUMENT EDGAR
- Sep 18, 2026DEFA14A EDGAR
- Sep 11, 2026EFFECT EDGAR
- Sep 11, 2026424B3 EDGAR
- Sep 9, 2026S-3/A EDGAR
- Sep 2, 2026SCHEDULE 13D/A EDGAR
- Sep 2, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 27, 202610-K EDGAR
- Aug 24, 2026DEF 14A EDGAR
- Aug 21, 2026S-3/A EDGAR
- Aug 19, 20268-K EDGAR
- Aug 12, 2026PRE 14A EDGAR
- Aug 6, 20268-K EDGAR
- Aug 5, 2026SCHEDULE 13G/A EDGAR
- Jul 31, 2026S-3 EDGAR
- Jul 29, 20268-K EDGAR
The 348 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
58 open-market trades by officers, directors and large owners since October 2021: 10 buys and 48 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | MAYER STEVEN FDirector | Buy | 54,875 | $0.56 | $30.7K | Form 4 |
| Feb 19, 2026 | MAYER STEVEN FDirector | Buy | 69,000 | $0.53 | $36.6K | Form 4 |
| Feb 18, 2026 | MAYER STEVEN FDirector | Buy | 126,125 | $0.53 | $66.8K | Form 4 |
| Nov 19, 2025 | La Neve Stephen R.CEO | Buy | 20,000 | $0.97 | $19.4K | Form 4 |
| Jun 13, 2025 | WHITTERS JOSEPH EDirector | Buy | 50,000 | $1.25 | $62.5K | Form 4 |
| Sep 4, 2024 | Pervaiz AliSVP Chief Financial Officer | Sale | 8,404 | $2.06 | $17.3K | Form 4 |
| Jun 4, 2024 | Pervaiz AliSVP Chief Financial Officer | Sale | 2,701 | $1.70 | $4.6K | Form 4 |
| May 29, 2024 | WHITTERS JOSEPH EDirector | Buy | 50,000 | $1.58 | $79.0K | Form 4 |
| May 28, 2024 | WHITTERS JOSEPH EDirector | Buy | 50,000 | $1.54 | $77.0K | Form 4 |
| Mar 1, 2024 | Hoge MichaelSenior VP Global Operations | Sale | 11,991 | $2.59 | $31.1K | Form 4 |
| Jan 3, 2024 | Corradetti GInaVP, CAO and Controller | Sale | 14,129 | $2.74 | $38.7K | Form 4 |
| Jan 3, 2024 | Pervaiz AliSVP Chief Financial Officer | Sale | 2,116 | $2.74 | $5.8K | Form 4 |
| Dec 1, 2023 | Chalke SandeepSVP, Chief Commercial Officer | Sale | 26,799 | $1.70 | $45.6K | Form 4 |
| Dec 1, 2023 | Spine PatrickSVP, Chief Admin Officer | Sale | 14,832 | $2.47 | $36.6K | Form 4 |
| Dec 1, 2023 | Winter Suzanne CPresident and CEO | Sale | 65,390 | $2.47 | $161.5K | Form 4 |
| Dec 1, 2023 | Pervaiz AliSVP Chief Financial Officer | Sale | 13,463 | $2.47 | $33.3K | Form 4 |
| Dec 1, 2023 | Chalke SandeepSVP, Chief Commercial Officer | Sale | 14,585 | $2.47 | $36.0K | Form 4 |
| Dec 1, 2023 | Chew JesseChief Legal Officer | Sale | 29,770 | $2.47 | $73.5K | Form 4 |
| Dec 1, 2023 | Hoge MichaelSenior VP Global Operations | Sale | 19,212 | $2.47 | $47.5K | Form 4 |
| Nov 1, 2023 | Winter Suzanne CPresident and CEO | Sale | 38,338 | $2.57 | $98.5K | Form 4 |
All 58 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- TCW GROUP INCSCHEDULE 13D/A, 4 filings Jun 17, 2025 to Sep 2, 202698
- Neuberger BermanSCHEDULE 13G/A, 6 filings Feb 11, 2022 to Aug 5, 202699
- BlackRockSCHEDULE 13G/A, 5 filings Feb 7, 2022 to Jul 27, 2026100
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 13, 2024 to Mar 26, 2026101
- Aevum Pension FundSCHEDULE 13G/A, 3 filings Oct 2, 2024 to Oct 2, 2025102
- Archon Capital Management LLCSC 13G/A, 3 filings Feb 13, 2023 to Sep 6, 2024103
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Tcw Group Inc | 18,942,059 | $4.1M | 0.0% | +3,474,107 |
| Neuberger Berman Group LLC | 6,073,663 | $1.6M | 0.0% | +218,599 |
| Armistice Capital, LLC | 5,736,000 | $1.5M | 0.0% | +100,000 |
| Weber Capital Management LLC /adv | 4,932,706 | $1.3M | 1.1% | −122,588 |
| Vanguard Capital Management LLC | 4,437,800 | $1.1M | 0.0% | +7,408 |
| BlackRock, Inc. | 3,266,185 | $842.0K | 0.0% | −5,192,224 |
| Aqr Capital Management LLC | 2,719,032 | $701.0K | 0.0% | +2,101,555 |
| Jane Street Group, LLC | 2,139,720 | $551.6K | 0.0% | New |
| Renaissance Technologies LLC | 2,065,284 | $532.4K | 0.0% | −225,700 |
| DAFNA Capital Management LLC | 1,680,508 | $433.2K | 0.1% | No change |
| UBS Group AG | 1,623,965 | $419.0K | 0.0% | +222,199 |
| Millennium Management LLC | 1,589,145 | $409.7K | 0.0% | New |
| Silverback Asset Management LLC | 1,450,000 | $373.8K | 1.4% | −200,000 |
| Squarepoint Ops LLC | 1,448,234 | $373.4K | 0.0% | +901,158 |
| Fmr LLC | 1,375,746 | $354.7K | 0.0% | +86,958 |
| Geode Capital Management, LLC | 1,189,377 | $306.7K | 0.0% | −1,191,462 |
| Kovack Advisors, Inc. | 1,050,896 | $272.7K | 0.0% | +312,800 |
| Susquehanna International Group, Llp | 825,604 | $212.8K | 0.0% | +791,827 |
| Goldman Sachs Group Inc | 802,957 | $207.0K | 0.0% | −58,678 |
| Vanguard Fiduciary Trust Co | 685,262 | $176.8K | 0.0% | −80,186 |
| Silverberg Bernstein Capital Management LLC | 658,915 | $169.9K | 0.1% | +3,234 |
| D. E. Shaw & Co., Inc. | 649,353 | $167.4K | 0.0% | −194,293 |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 500,000 | $128.9K | 0.0% | No change |
| State Street Corp | 485,866 | $125.3K | 0.0% | −1,531,787 |
| Assenagon Asset Management S.A. | 408,028 | $105.2K | 0.0% | +204,013 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How ACCURAY INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARACCURAY INC1
- CIK0001138723
- Employer ID (EIN)20-83700415
- Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsJune 301
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address1240 Deming Way, Madison, WI 537171
- Phone608-824-28001
- Shares outstanding119,439,307 shares as of Aug 21, 20265
- Public float$86.9M as of Dec 31, 20255
- AuditorGRANT THORNTON LLP, San Jose, California PCAOB ID 248; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceMar 6, 20021
- Filings1,464 in all: 4 (694), 8-K (289), SC 13G/A (81), 10-Q (59), 3 (58), SC 13G (38), S-8 (25), DEFA14A (24)1
All 46 form types
10-K (20), DEF 14A (20), 4/A (13), CORRESP (13), SD (13), UPLOAD (13), ARS (10), 425 (9), CT ORDER (9), 144 (8), 3/A (8), SCHEDULE 13G/A (8), S-1/A (6), EFFECT (5), 424B3 (4), REGDEX (3), S-3 (3), SCHEDULE 13D/A (3), SCHEDULE 13G (3), 10-K/A (2), 5 (2), NT 10-K (2), NT 10-Q (2), PRE 14A (2), S-3/A (2), 10-Q/A (1), 144/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), FWP (1), REGDEX/A (1), S-1 (1), S-1MEF (1), S-4 (1), S-4/A (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Aug 27, 2026
Quarterly report (10-Q) May 6, 2026
Proxy statement (DEF 14A) Aug 24, 2026
Latest 8-K (8-K) Oct 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value per share | ARAY | Nasdaq |
From the cover page of the 10-K filed Aug 27, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks ACCURAY INC names in Item 1A of its 10-K filed Aug 27, 2026: 53 risks under these headings, as written.5
- Risks related to our business and results of operations
- Risks related to the regulation of our products and business
- Risks related to our common stock
- Risks Related to our Financing Transaction
- General Risks
- Risks Related to Our Business and Results of Operations
- We face risks related to the current global economic environment, including risks arising in connection with tariffs, inflation, recession or currency fluctuations, any of which could adversely affect our business, financial condition and results of operations by, among other things, delaying or preventing our customers from obtaining financing to purchase our products and services or implementing the required facilities to house our systems.
- If the CyberKnife or TomoTherapy platforms do not achieve widespread market acceptance, we will not be able to generate the revenue necessary to support our business.
- Our ability to achieve profitability depends in part on maintaining or increasing our gross margins on product sales and services, which we may not be able to achieve.
- We have substantial indebtedness in the form of a credit facility and may incur other debt in the future, which may adversely affect our financial condition and future financial results. In the past, we have not been in compliance with certain financial covenants relating to our indebtedness and have been required to obtain waivers to avoid defaulting under such indebtedness.
- Uncertainty or volatility in trade policy as well as enhanced international tariffs, including tariffs imposed by the United States and China that affect our products or components within our products, other trade barriers or a global trade war could decrease the volume of product sales in China and increase our costs and materially and adversely affect our business, financial condition and results of operations.
- Our operating results, including our cash flows, quarterly orders, revenues and margins fluctuate from quarter to quarter and may be unpredictable.
The other 47 risks
- Our industry is subject to intense competition and rapid technological change, which may result in products or new tumor treatments that are superior to the CyberKnife and TomoTherapy platforms. If we are unable to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands, our products may become obsolete or less useful and our operating results will suffer.
- We are subject to risks arising from our international operations, which may adversely affect our business, financial condition, and results of operations.
- Our results have been and may continue to be impacted by changes in foreign currency exchange rates.
- If we encounter manufacturing problems, or if our manufacturing facilities do not continue to meet federal, state or foreign manufacturing standards, we may be required to temporarily cease all or part of our manufacturing operations, which would result in delays and lost revenue.
- If we are unable to develop new products or enhance existing products to meet our customers’ needs and compete favorably in the market, we may be unable to attract or retain customers.
- If we do not effectively manage our growth, our business may be significantly harmed.
- We could become subject to product liability claims, product recalls, other field actions and warranty claims that could be expensive, divert management’s attention and harm our business.
- Our reliance on single‑source suppliers for critical components of the CyberKnife and TomoTherapy platforms could harm our ability to meet demand for our products in a timely and cost effective manner.
- We depend on key employees, the loss of whom would adversely affect our business. If we fail to attract and retain employees with the expertise required for our business, we may be unable to continue to grow our business.
- Disruption of critical information technology systems, infrastructure and data or cyberattacks or other security breaches or incidents could harm our business and financial condition.
- Any actual or perceived failure by us to comply with legal or regulatory requirements related to privacy, cybersecurity and data protection in one or multiple jurisdictions could result in proceedings, actions or penalties against us.
- We have incorporated and continue to work to further incorporate artificial intelligence into our products, services, and internal operations. Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business.
- Continued consolidation in the healthcare industry could have an adverse effect on our business, financial condition, or results of operations.
- If third‑party payors do not provide sufficient coverage and reimbursement to healthcare providers for use of the CyberKnife and TomoTherapy platforms or if the number of patients covered by health insurance reduces, demand for our products and our revenue could be adversely affected.
- The safety and efficacy of our products for certain uses is not yet supported by long‑term clinical data, and our products may therefore prove to be less safe and effective than initially thought.
- We are reliant on the timely, accurate, and consistent provision of outsourced services for various services and business functions, as well as third parties who perform shipping and logistics functions on our behalf. Failures, disruptions, terminations, or replacements of our outsourcing providers or our logistics providers have occurred and could occur in the future, which could adversely impact our business.
- Third parties may claim we are infringing their intellectual property or that we are operating outside the scope of or violating a license or other agreement relating to their intellectual property, and we could suffer significant audit, litigation or licensing expenses, incur liabilities associated with indemnification obligations to customers, experience disruptions in the supply of components of our products or related services, or be prevented from selling our product or components of our product.
- We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
- It is difficult and costly to protect our intellectual property and our proprietary technologies and we may not be able to ensure their protection.
- Unfavorable results of legal proceedings could materially and adversely affect our financial condition.
- Because the majority of our product revenue is derived from sales of the CyberKnife and TomoTherapy platforms, which have a long and variable sales and installation cycle, our revenues and cash flows may be volatile and difficult to predict.
- We depend on third‑party distributors to market and distribute our products in international markets. If our distributors fail to successfully market and distribute our products, our business will be materially harmed.
- The high unit price of the CyberKnife and TomoTherapy platforms, as well as other factors, may contribute to substantial fluctuations in our operating results, which could adversely affect our stock price.
- As a strategy to assist our sales efforts, we may offer extended payment terms, which may potentially result in higher days sales outstanding, reduced cash flows in a particular period and greater payment defaults.
- We have entered into certain relationships with collaborators, partnerships, strategic alliances, joint venture partners and other third parties, which are outside of our full control and may harm our existing business if we fail to realize the expected benefits of such relationships.
- We may attempt to acquire new businesses, products or technologies, including forming joint ventures, and if we are unable to successfully complete these acquisitions or to integrate acquired businesses, products, technologies or employees, we may fail to realize expected benefits or harm our existing business.
- Our ability to raise capital or obtain financing in the future may be limited, and our failure to raise capital when needed could prevent us from executing our growth strategy.
- We may not be able to fully utilize certain tax loss carryforwards.
- We are subject to the tax laws of various foreign jurisdictions, as well as within the United States, which are subject to unanticipated changes and interpretation and could harm our future results.
- Risks Related to the Regulation of our Products and Business
- Modifications, upgrades, new indications and future products related to the CyberKnife or TomoTherapy Systems or the Precision Treatment Planning and iDMS Data Management System software may require new FDA 510(k) clearances or premarket approvals and similar licensing or approvals in international markets. Such modifications, or any defects in design, manufacture or labeling may require us to recall or cease marketing the affected systems or software until approvals or clearances are obtained.
- We are subject to federal, state and foreign laws and regulations applicable to our operations, the violation of which could result in substantial penalties and harm our business.
- Laws and ethical rules governing interactions with healthcare providers.
- Laws protecting patient health information.
- If we or our distributors do not obtain and maintain the necessary regulatory approvals in a specific country, we will not be able to market and sell our products in that country.
- Healthcare reform legislation could adversely affect demand for our products, our revenue and our financial condition.
- Risks Related to Our Common Stock
- The price of our common stock is volatile and may continue to fluctuate significantly, which could lead to losses for stockholders.
- If we do not regain compliance with or continue to satisfy Nasdaq’s continued listing standards and other Nasdaq rules, our common stock could be delisted, which would harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock.
- Future issuances of shares of our common stock could dilute the ownership interests of our stockholders.
- The exercise of outstanding warrants for our common stock would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders.
- Provisions in the Financing Agreement for our Credit Facilities, our certificate of incorporation and our bylaws could discourage or prevent a takeover, even if an acquisition would be beneficial in the opinion of our stockholders.
- There can be no assurance that the Financing Transaction will be successfully consummated or achieve the anticipated results.
- If the Financing Transaction is consummated, our stockholders will experience substantial dilution as a result of any conversion of the Series A Convertible Preferred Stock or the exercise of the July 2026 Warrants.
- TCW Asset Management Company LLC and its affiliates will have significant influence over us following the conversion of the Series A Convertible Preferred Stock and the exercise of the July 2026 Warrants, if any, and their interests may conflict with those of our other stockholders in the future.
- Our liquidity could be adversely impacted by adverse conditions in the financial markets.
- Our operations are vulnerable to interruption or loss because of climate change, natural disasters, global or regional health pandemics or epidemics, terrorist acts and other events beyond our control, which has impacted and could in the future adversely affect our business.
- Changes in interpretation or application of generally accepted accounting principles may adversely affect our operating results.
- We have not paid dividends in the past and do not expect to pay dividends in the foreseeable future.
Legal proceedings
Refer to Note 8. Commitments and Contingencies, to the consolidated financial statements for a description of certain legal proceedings currently pending against the Company. From time to time, we are involved in legal proceedings arising in the ordinary course of our business.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARACCURAY INC filings on SEC EDGAR
- 2SEC EDGARACCURAY INC 10-K for fiscal 2026
- 3SEC EDGARACCURAY INC filings on SEC EDGAR
- 4
- 5
- 6SEC EDGARACCURAY INC 10-K for fiscal 2019
- 7SEC EDGARACCURAY INC 10-K for fiscal 2020
- 8SEC EDGARACCURAY INC 10-K for fiscal 2021
- 9SEC EDGARACCURAY INC 10-K for fiscal 2022
- 10SEC EDGARACCURAY INC 10-K for fiscal 2024
- 11SEC EDGARACCURAY INC 10-Q for fiscal 2025
- 12SEC EDGARACCURAY INC 10-Q for fiscal 2026
- 13SEC EDGARACCURAY INC 10-K for fiscal 2019
- 14SEC EDGARACCURAY INC 10-K for fiscal 2025
- 15
- 16
- 17
- 18
- 19SEC EDGARSuzanne C. Winter, President
- 20SEC EDGARAli Pervaiz, Chief financial officer
- 21
- 22
- 23
- 24
- 25
- 26
- 27SEC EDGARKelly Londy, Chief operating officer
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39SEC EDGARAlaleh Nouri, SVP & Interim GC
- 40SEC EDGARGregory Lichtwardt, EVP, Operations
- 41
- 42
- 43
- 44
- 45
- 46
- 47SEC EDGARHolly Grey, SVP Finance
- 48SEC EDGAREric Lindquist, Sr. VP, CMO
- 49
- 50
- 51SEC EDGARJohn Adler, Board Member
- 52SEC EDGARSteven F. Mayer, Board member
- 53SEC EDGARChan Galbato, Board member
- 54SEC EDGARRobert Kill, Board member
- 55SEC EDGARByron C. Scott, Board member
- 56SEC EDGARMika Nishimura, Board member
- 57SEC EDGARGrand Anne Bryce Le, Board member
- 58SEC EDGARJoshua Levine, Board member
- 59SEC EDGARJames M. Hindman, Board member
- 60SEC EDGARBeverly A. Huss, Board member
- 61SEC EDGARJoseph E. Whitters, Board member
- 62SEC EDGAREmad T. Rizk, Board member
- 63SEC EDGARRichard Pettingill, Board member
- 64SEC EDGARJack Goldstein, Board member
- 65SEC EDGARPeter Fine, Board member
- 66SEC EDGARDennis L. Winger, Board member
- 67SEC EDGARLouis J. Lavigne Jr., Board member
- 68SEC EDGARElizabeth H. Davila, Board member
- 69SEC EDGARJohn P. Wareham, Board member
- 70SEC EDGARJohn Adler, Board member
- 71SEC EDGARLi Yu, Board member
- 72SEC EDGARRobert S. Weiss, Board member
- 73SEC EDGARTed T.c. Tu, Board member
- 74SEC EDGARWayne Wu, Board member
- 75SEC EDGARJesse Chew, General counsel
- 76SEC EDGARAlaleh Nouri, General counsel
- 77SEC EDGARDarren J. Milliken, General counsel
- 78
- 79SEC EDGARExecutive or director change
- 80
- 81
- 82SEC EDGARListing notice or transfer
- 83
- 84
- 85
- 86SEC EDGARExecutive or director change
- 87SEC EDGAREntered a material agreement
- 88SEC EDGARRegulation FD disclosure
- 89SEC EDGARExecutive or director change
- 90SEC EDGARRegulation FD disclosure
- 91NasdaqNasdaq calendar
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103